What is GraphWear Technologies?
GraphWear Technologies is a pioneering health-tech enterprise dedicated to the development of innovative, non-invasive glucose monitoring solutions. By focusing on the intersection of material science and medical diagnostics, the company aims to eliminate the traditional pain points associated with diabetes management. Their core technology is designed to provide users with a seamless, efficient, and comfortable experience, thereby improving long-term health outcomes for individuals living with chronic conditions. The company operates within the high-growth medical device market, targeting a demographic that demands both clinical accuracy and user-friendly design in their daily health monitoring tools.
How much funding has GraphWear Technologies raised?
GraphWear Technologies has raised a total of $24.7M across 2 funding rounds:
Series A
$4.2M
Series B
$20.5M
Series A (2018): $4.2M with participation from BioInnovation Capital and Mission Bay Capital
Series B (2021): $20.5M led by Mayfield, VSC Ventures, BioInnovation Capital, and Builders VC
Key Investors in GraphWear Technologies
BioInnovation Capital
BioInnovation Laboratories specializes in in vitro testing, research, development, and consulting services for clients in the pharmaceutical, cosmetic, personal health care, and specialty chemical industries.
Mission Bay Capital
Mission Bay Capital is an early stage life science venture capital firm that focuses on enabling innovative advancements in the life sciences sector.
Mayfield
Mayfield is a Menlo Park-based venture capital firm that raises dedicated funds to invest in early-stage technology companies, backing enterprise, consumer, and infrastructure founders.
What's next for GraphWear Technologies?
With the recent infusion of capital, GraphWear Technologies is poised to scale its operational capabilities and expand its market reach. The strategic focus will likely shift toward clinical validation, regulatory approval processes, and the commercialization of its next-generation biosensor suite. By optimizing its manufacturing processes and deepening its research and development efforts, the company aims to solidify its competitive advantage in the glucose monitoring space. Investors are closely watching how the firm will utilize these resources to navigate the complex regulatory environment and achieve widespread adoption among both clinical providers and end-users, ultimately aiming to redefine the standard of care for diabetes management.
See full GraphWear Technologies company page
